ライフサイエンスコーパス: recurrence-free survival

1 d cohorts (n = 592 with DRFS, n = 1,050 with recurrence-free survival).

2 suitable treatment regimens that can improve recurrence-free survival.

3 comes of the study were overall survival and recurrence-free survival.

4 ffected microwave ablation (MWA) success and recurrence-free survival.

5 ->A, located in exon 2), was associated with recurrence-free survival.

6 ation was not associated with improved local recurrence-free survival.

7 -3 and undetectable PTEN exhibited decreased recurrence-free survival.

8 sectable ICCA demonstrated promising disease recurrence-free survival.

9 ent-refractory high Ki-67 scores and shorter recurrence-free survival.

10 way activation profiles were associated with recurrence-free survival.

11 tionship between gamma-OHPdG and survival or recurrence-free survival.

12 d the interim analysis efficacy boundary for recurrence-free survival.

13 ght may enhance detection as well as prolong recurrence-free survival.

14 esulting score was prognostic of overall and recurrence-free survival.

15 ize (P = 0.016) independently predicted poor recurrence-free survival.

16 The primary endpoint was recurrence-free survival.

17 ne treatment had a significant advantage for recurrence-free survival.

18 efficacy of adjuvant mitotane in prolonging recurrence-free survival.

19 ionship between intratumor heterogeneity and recurrence-free survival.

20 cystoscopy in terms of cancer detection and recurrence-free survival.

21 n between class I or class II mismatches and recurrence-free survival.

22 (ALDH1a2), was also associated with shorter recurrence-free survival.

23 doxorubicin) for clear cell sarcoma improves recurrence-free survival.

24 gnificant prognostic markers for overall and recurrence-free survival.

25 expression was associated with a decrease in recurrence-free survival.

26 all, disease-free, recurrence-free, or local recurrence-free survival.

27 C patients and yielded significantly shorter recurrence-free survival.

28 the tumor is critical to the patient's tumor recurrence-free survival.

29 cal cohorts, wherein it associated with poor recurrence-free survival.

30 lly significant improvement in breast cancer recurrence-free survival.

31 ncluded overall survival and disease-free or recurrence-free survival.

32 esulting score was prognostic of overall and recurrence-free survival.

33 patients achieved the optimal outcome of 1-y recurrence-free survival.

34 ent completion, and patients who achieve 1-y recurrence-free survival.

35 c TGFBR2 expression correlated with improved recurrence-free survival.

36 Overall survival (OS) and recurrence-free survival.

37 eater than that from tamoxifen alone (HR for recurrence-free survival 0.52, 0.39-0.68, p<0.0001; HR f

38 eceptor concentration (hazard ratio [HR] for recurrence-free survival 0.58, 95% CI 0.50-0.67, p<0.000

39 Probabilities of overall and recurrence-free survival 10 years after first treatment

40 0.58; P<.001) and disease recurrence (median recurrence-free survival, 13.8 years for radiotherapy vs

41 .1%) vs. 62/86 (72.1%); P=0.013], and 1-year recurrence free survival [20% (+/-0.06) vs. 48.2% (+/-0.

42 Recurrence-free survival 24 months after brachytherapy w

43 R0 resection (88% vs 88%, P = 0.999), median recurrence-free survival (33 vs 27 months, P = 0.502), a

44 compared with the two control groups (median recurrence-free survival, 42 months, as compared with 10

45 c survival (73.2% vs. 75.3%, p = 0.844), and recurrence-free survival (61.2% vs. 66.3%, p = 0.742).

46 c survival compared with patients with IPNI (recurrence-free survival, 61% vs 76%; P = .009; disease-

47 overall survival (77.7% vs 76.0%, P = 0.64), recurrence-free survival (72.7% vs 71.2%, P = 0.70), or

48 iated tumors showed a trend toward decreased recurrence-free survival (8 vs 28 months, P = 0.075).

49 4 receiving LRT had similar 1, 3, and 5-year recurrence-free survival (89%, 77%, 68% vs 85%, 75%, 68%

50 to LRT; and had superior 1-, 3-, and 5-year recurrence-free survival (92%, 79%, and 73% vs 81%, 63%,

51 ssessed the association between genotype and recurrence-free survival, adjusted for baseline characte

52 lantation at 12 US centers had a 65% rate of recurrence-free survival after 5 years, showing this the

53 IgA was the strongest negative predictor of recurrence-free survival after achieving partial remissi

54 Though there were no differences in recurrence-free survival after curative therapy (median,

55 s for prediction of tumor aggressiveness and recurrence-free survival after liver transplantation.

56 n was associated with a similar detriment in recurrence-free survival (AHR, 2.85; 95% CI, 1.75-4.63)

57 rs correlated with a significant decrease in recurrence free survival and a significant increase in t

58 ma recurred in 11 patients (25%), with a 64% recurrence-free survival and 59% overall survival at 3 y

59 tions for pancreatic NETs are prognostic for recurrence-free survival and can be adopted in clinical

60 ts with CSCC and CPNI had poorer mean 5-year recurrence-free survival and disease-specific survival c

61 Adjuvant therapy with imatinib prolongs recurrence-free survival and may improve overall surviva

62 the effects of cisplatin and carboplatin on recurrence-free survival and OS in mice bearing BRCA1/2-

63 Primary endpoints were recurrence-free survival and overall survival estimated

64 NAMS is an excellent predictor of recurrence-free survival and overall survival in human l

65 ween this gene expression signature and both recurrence-free survival and overall survival in lung ca

66 Recent studies have demonstrated increased recurrence-free survival and overall survival rates in p

67 with adjuvant imatinib resulted in improved recurrence-free survival and overall survival, whereas d

68 Recurrence-free survival and post-LT recurrence were com

69 Recurrence-free survival and recurrence rates.

70 associated with poorer overall survival and recurrence-free survival and remained an independent pro

71 -free survival, 0.74 (95% CI, 0.55-0.99) for recurrence-free survival, and 0.75 (95% CI, 0.54-1.05) f

72 ere tested for best-corrected visual acuity, recurrence-free survival, and adverse events scored by u

73 The primary endpoint was recurrence-free survival, and analysis was by intention

74 mary endpoints were 5-year overall survival, recurrence-free survival, and freedom from recurrence ra

75 Disease-free survival, recurrence-free survival, and overall survival by dietar

76 trend for reduced recurrence risk and longer recurrence-free survival as the number of adverse allele

77 ral, trials should use time to recurrence or recurrence-free survival as the primary end point and ti

78 The primary outcome was recurrence-free survival assessed after database cut-off

79 The primary endpoint was recurrence-free survival, assessed by an independent rev

80 but question certain others (eg, in 15-year recurrence-free survivals assuming finasteride does alte

81 splanted for cholangiocarcinoma, with a 100% recurrence free survival at a mean follow up of 18 month

82 failed to confirm significantly better tumor recurrence- free survival at 1 year.

83 ucing tumors also had significantly superior recurrence-free survival at 1, 3, and 5 years (88%, 74%,

84 Recurrence-free survival at 2 years was similar (47% and

85 Positive RVI score also portended lower recurrence-free survival at 3 years versus negative RVI

86 Recurrence-free survival at 3 years was 86% (95% CI 74-1

87 res: The primary end point was breast cancer recurrence-free survival (BCRFS).

88 We noted no difference in median recurrence-free survival between the two groups (33.3 mo

89 ogic prognostic factors (10-year biochemical recurrence-free survival [bRFS], 29%; distant metastasis

90 wed independent substratification of reduced recurrence-free survival by Kaplan-Meier analysis.

91 pendently associated with the highest 2-year recurrence-free survival by multivariate analyses in two

92 Excellent long-term disease recurrence-free survival can be achieved in selected pat

93 Imatinib significantly improved recurrence-free survival compared with placebo (98% [95%

94 juvant treatment with imatinib would improve recurrence-free survival compared with placebo after res

95 matinib therapy is safe and seems to improve recurrence-free survival compared with placebo after the

96 treatment with ipilimumab results in longer recurrence-free survival compared with that for treatmen

97 verall (OS), recurrence-free, and liver-only recurrence-free survival, compared with non-PSH (P = 0.5

98 Median recurrence-free survival could not have been estimated i

99 years, high-risk patients, with the shortest recurrence-free survival, demonstrated increased activat

100 The cumulative VT recurrence-free survival did not differ by procedural su

101 Outcomes included recurrence-free survival, disease-specific survival, and

102 biomarker status is a prognostic factor for recurrence-free survival, distant metastasis disease-fre

103 for disease-specific survival (DSS), distant recurrence-free survival (DRFS) and local recurrence-fre

104 The <8-mm group had reduced distant recurrence-free survival (DRFS) compared with the 8- to

105 A multigene predictor for distant recurrence-free survival (DRFS) was developed by the sup

106 for disease-specific survival (DSS), distant recurrence-free survival (DRFS), and local recurrence-fr

107 e recurrence-free survival (RFS) and distant recurrence-free survival (DRFS).

108 Patients with FN AUS had recurrence-free survival equivalent to patients with pat

109 f 2.74 years (IQR 2.28-3.22), there were 528 recurrence-free survival events (234 in the ipilimumab g

110 At final analysis, 464 recurrence-free survival events had occurred (270 in the

111 Median recurrence-free survival for carriers of the risk allele

112 The untreated group showed 49% v 57% 10-year recurrence-free survival for EGFR low versus high (P = .

113 Adjuvant ipilimumab significantly improved recurrence-free survival for patients with completely re

114 olecular signature predicted poor outcome of recurrence-free survival for patients with prostate canc

115 Estimated 5-year recurrence-free survival for the stapled anastomosis, in

116 Study endpoints included second local recurrence-free survival for these 61 patients and disea

117 r interactions that resulted in variation in recurrence-free survival from 12 to 42 months, depending

118 Noninducible patients with LVEF>30% had a recurrence-free survival from cardiac death of 90% (95%

119 fer by age for response rate, progression or recurrence free-survival (hazard ratio, 0.70 for FOLFOX4

120 ients with high SULF1 expression have poorer recurrence-free survival (hazard ratio 4.1, 95% confiden

121 ls, tumor size 3 cm or more predicted poorer recurrence-free survival (hazard ratio: 1.60, 95% CI: 1.

122 sociated with increased local and in-transit recurrence-free survival [hazard ratio (HR) = 0.54; P =

123 The miR-21(High) group exhibited shorter recurrence-free survival [hazard ratio (HR), 1.71; P < 0

124 be a significantly poor prognostic factor of recurrence free survival (HR = 2.40, P = 0.005, 95%CI: 1

125 ard ratio [HR] = 2.13, P = .009) and reduced recurrence-free survival (HR = 1.70, P = .046) and MSS (

126 0.002)] and in tumor stroma from TNBC cases [recurrence-free survival: HR, 2.59 (P = 0.013); BC-speci

127 mal growth factor receptor 2-negative cases [recurrence-free survival: HR, 3.67 (P = 0.006); BC-speci

128 Randomized data show improved recurrence free survival in patients receiving imatinib

129 ure was an independent prognostic factor for recurrence-free survival in a publicly available head an

130 and low TbetaRIII levels predicted decreased recurrence-free survival in breast cancer patients.

131 ized treatment frequency showed no effect on recurrence-free survival in either treatment subgroup.

132 a potentially useful tool for prediction of recurrence-free survival in lung and breast cancer and v

133 ant and independent prognostic tool of human recurrence-free survival in lung and breast cancers.

134 ctor CD8(+) T cells (T(eff)) predicts longer recurrence-free survival in many types of human cancer,

135 teristic curves = 99% and 92%), and stratify recurrence-free survival in patients from two independen

136 ultiple studies have reported improved local recurrence-free survival in patients who received adjuva

137 elopments in radiation therapy have improved recurrence-free survival in patients with chordomas.

138 A possible improvement in recurrence-free survival in patients with early stage di

139 in/IGF-I gene expression signature predicted recurrence-free survival in patients with ER(+) breast c

140 ead acceptance that RAI improves overall and recurrence-free survival in patients with metastatic dis

141 ositively correlated with higher overall and recurrence-free survival in patients with prostate cance

142 Adjuvant mitotane may prolong recurrence-free survival in patients with radically rese

143 atus and assessed their prognostic effect on recurrence-free survival in premenopausal women at risk

144 r analysis confirmed this result, with a 2-y recurrence-free survival in the (131)I-lipiodol and lipi

145 Recurrence-free survival in the 307 study patients was 6

146 and fruit intake with greater likelihood of recurrence-free survival in women who have been diagnose

147 it in terms of overall, cancer-specific, and recurrence-free survivals in patients with pT3N0M0 UTUC

148 ant post-RFA factors that related to reduced recurrence-free survival included an unfavorable uptake

149 Before RFA, factors predicting greater local recurrence-free survival included initial lesion size le

150 ssociated with an improved overall and liver recurrence-free survival (liver RFS) and disease-specifi

151 sociations with the primary endpoints: local recurrence-free survival (LRFS) and disease-specific sur

152 3-year disease-free survival (DFS) and local recurrence-free survival (LRFS).

153 t recurrence-free survival (DRFS), and local recurrence-free survival (LRFS).

154 nt recurrence-free survival (DRFS) and local recurrence-free survival (LRFS).

155 all survival, disease-specific survival, and recurrence-free survival (median follow-up period, 70.8

156 Efficacy end points were local recurrence-free survival, metastasis-free survival, canc

157 urvival (MTV: P = 0.001; TGV: P = 0.004) and recurrence-free survival (MTV: P = 0.001, TGV; P = 0.002

158 herapy was not significantly associated with recurrence-free survival (multivariate HR, 0.93; 95% CI,

159 iver operating curve with 1-, 3-, and 5-year recurrence-free survival of 90%, 73%, and 49%, respectiv

160 ay offer a new treatment strategy to improve recurrence-free survival of breast cancer patients.

161 y in most tumors, and it also predicted long recurrence-free survival of HER2-negative, stage III bre

162 aneous pulmonary metastases while prolonging recurrence-free survival only in immunocompetent mice.

163 d USP6 rearrangements did not correlate with recurrence-free survival, or with other clinicopathologi

164 Endpoints were recurrence-free survival overall survival, and rate of C

165 am resulted in significantly higher rates of recurrence-free survival, overall survival, and distant

166 ded prostate-specific antigen (PSA) relapse, recurrence-free survival, overall survival, freedom from

167 l: Akt Ser(473) (overall survival P < 0.001, recurrence-free survival P < 0.0009), 4EBP1 Thr(37/46) (

168 IF4G Ser(1108) (overall survival P < 0.0017, recurrence-free survival P < 0.0072), and p70S6 Thr(389)

169 BP1 Thr(37/46) (overall survival P < 0.0110, recurrence-free survival P < 0.0106), eIF4G Ser(1108) (o

170 p70S6 Thr(389) (overall survival P < 0.0085, recurrence-free survival P < 0.0296).

171 colectomy patients had significantly reduced recurrence free survival (P = 0.032) but not stoma free

172 free survival (DFS) (P < 0.001) and regional recurrence-free survival (P < 0.001).

173 0 months, ILC patients tended to have longer recurrence-free survival (P = .004) and overall survival

174 This signature also significantly predicted recurrence-free survival (P = .029) and breast cancer -s

175 istant recurrences, and significantly better recurrence-free survival (P = 0.0001).

176 promoter mutations, correlated with reduced recurrence-free survival (P = 0.001).

177 iated with low survival (P < 0.0001) and low recurrence-free survival (P = 0.007).

178 tatistically significant difference in local recurrence-free survival (P = 0.13).

179 0), disease-specific survival (P =.022), and recurrence-free survival (P =.016).

180 was associated with similar improvements in recurrence-free survival (P for trend = .03) and overall

181 breast cancers was associated with decreased recurrence-free survival, particularly in patients treat

182 There is a need to develop a guideline for recurrence-free survival period for nonhepatic malignanc

183 and cyclin D1, and reduced Numb, had reduced recurrence-free survival probability (HR = 4.35).

184 Slit2 correlated positively with overall and recurrence-free survival, providing clinical validation

185 The 1-year recurrence-free survival rate for patients with a CR was

186 ll tumors had the best outcome (5-year local recurrence-free survival rate of 91%).

187 mphatic density revealed significantly lower recurrence-free survival rates (P = 0.041) in C-MIN with

188 nts with unlimited epicardial RFA had better recurrence-free survival rates (P<0.001).

189 vant therapy with imatinib mesylate improves recurrence-free survival rates and may improve overall s

190 The 5-y recurrence-free survival rates in the (131)I-lipiodol an

191 fter therapy, respectively; post-transplant, recurrence-free survival rates were 78% and 65%, respect

192 The 5-year locoregional recurrence-free survival rates were also not different b

193 Patient characteristics and recurrence-free survival rates were compared with those

194 all survival, disease-specific survival, and recurrence-free survival rates were not statistically di

195 3sigma expression levels predict overall and recurrence-free survival rates, tumour glucose uptake an

196 ntified with the longest and shortest 5-year recurrence-free survival, respectively, within the age a

197 l (OS), disease-specific survival (DSS), and recurrence free survival (RFS) were assessed using the K

198 c significance for overall survival (OS) and recurrence free survival (RFS) were determined by Cox pr

199 disease-specific survival (DSS P<0.001) and recurrence-free survival (RFS P<0.001).

200 1.92), DFS (HR: 1.45, 95% CI: 1.15-1.84) and recurrence-free survival (RFS) (HR: 1.32, 95% CI: 0.98-1

201 Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after resection of locali

202 d that 1 year of adjuvant imatinib prolonged recurrence-free survival (RFS) after resection of primar

203 The estimated 15-year recurrence-free survival (RFS) and cancer-specific survi

204 Recurrence-free survival (RFS) and cancer-specific survi

205 Recurrence-free survival (RFS) and cancer-specific survi

206 Kaplan-Meier product was used to calculate recurrence-free survival (RFS) and distant recurrence-fr

207 HD7 expression was associated with increased recurrence-free survival (RFS) and overall survival (OS)

208 Recurrence-free survival (RFS) and overall survival (OS)

209 Recurrence-free survival (RFS) and overall survival (OS)

210 e survival (DFS), overall survival (OS), and recurrence-free survival (RFS) by treating neuropathy st

211 The prognostic analyses showed increased recurrence-free survival (RFS) for MSI-H patients versus

212 25[OH]D) levels on overall survival (OS) and recurrence-free survival (RFS) in NSCLC patients.

213 te the effect of KIT and PDGFRA mutations on recurrence-free survival (RFS) in patients with gastroin

214 se; how best to leverage this for predicting recurrence-free survival (RFS) is not established.

215 tients with low CHD5 expression had a median recurrence-free survival (RFS) of 5.3 vs 15.4 months for

216 red for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable

217 patients with mutant RAS (P = 0.002); 3-year recurrence-free survival (RFS) rates were 33.5% with wil

218 The 1-, 3-, and 5-year recurrence-free survival (RFS) rates were 96%, 60%, and

219 ar overall survival (OS) was 58% and 10 year recurrence-free survival (RFS) was 62%.

220 At a median of 28 months postoperation, recurrence-free survival (RFS) was 88.7%.

221 Recurrence-free survival (RFS) was a secondary end point

222 icopathologic data, recurrence patterns, and recurrence-free survival (RFS) were analyzed.

223 Their overall survival (OS) and recurrence-free survival (RFS) were compared.

224 Overall survival (OS) and recurrence-free survival (RFS) were estimated using the

225 -treat and censored analyses of on-treatment recurrence-free survival (RFS) were performed, and explo

226 ical and pathologic factors with SLN status, recurrence-free survival (RFS), and melanoma-specific su

227 The primary objective was recurrence-free survival (RFS), and the secondary object

228 Recurrence-free survival (RFS), disease-specific surviva

229 Recurrence-free survival (RFS), disease-specific surviva

230 Recurrence-free survival (RFS), distant metastasis (DM),

231 factors were independent predictors of worse recurrence-free survival (RFS), namely, an NLR >/= 5 (P

232 his article reports the interim analysis for recurrence-free survival (RFS), which was planned after

233 luded DF-free survival, failure pattern, and recurrence-free survival (RFS).

234 The primary end point was recurrence-free survival (RFS).

235 Primary outcome measurement was recurrence-free survival (RFS).

236 ic therapy after liver resection to increase recurrence-free survival (RFS).

237 Recurrence-free survival (RFS).

238 The primary end point was recurrence-free survival (RFS).

239 The primary end point was 12-month HG recurrence-free survival (RFS).

240 estimated, which can have an impact on their recurrence-free survival (RFS).

241 ors (AIs) have been associated with superior recurrence-free survival (RFS).

242 The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT)

243 cs; P <.0001), OS (57% v 66%; P <.0001), and recurrence-free survival (RFS; 56% v 64%, P =.012).

244 , 1.8; 95% CI, 1.1 to 2.5) predicted a lower recurrence-free survival (RFS; all P < .01).

245 Recurrence-free survival (RFS; primary end point), dista

246 Recurrence-free survivals (RFS) were calculated using th

247 ent and tumor characteristics, and outcomes (recurrence-free survival [RFS] and overall survival [OS]

248 -specific survival (MSS), DFS, regional node recurrence-free survival (RNRFS) and DRFS compared with

249 A Kaplan-Meier analysis of recurrence-free survival showed that the presence of tGI

250 , conversion from laparoscopy to laparotomy, recurrence-free survival, site of recurrence, and patien

251 tio of less than 1 showed dramatically lower recurrence-free survival than did patients with a ratio

252 with MSI-L and/or EMAST had shorter times of recurrence-free survival than patients with high levels

253 3) had a significantly decreased biochemical recurrence-free survival than those with a lower RSG 3 p

254 After 2 years of recurrence-free survival, the cumulative risk of recurre

255 n a significant, nearly 30-month decrease in recurrence-free survival time (P-value: 0.034 and 0.007

256 aging and invasiveness, predicting a shorter recurrence-free survival time in noninvasive bladder can

257 patients had tumor recurrence with a median recurrence-free survival time of 3.6 months (95% CI, 2.9

258 Recurrence-free survival time was not significantly diff

259 DDIT4 expression is related to the outcome (recurrence-free survival, time to progression and overal

260 inical course and estimate overall survival, recurrence-free survival, time with an intact breast, an

261 Recurrence-free survival times from alternative surveill

262 patients with stage III disease whose 5-year recurrence-free survival was >88% and for whom adjuvant

263 For ACAIS, recurrence-free survival was 100% at 1 month and 96% (95

264 disease-specific survival was 30% and 5-year recurrence-free survival was 18%.

265 Median recurrence-free survival was 26.1 months (95% CI 19.3-39

266 Median recurrence-free survival was 3.0 years in the observatio

267 n follow-up of 5.3 years, the 5-year rate of recurrence-free survival was 40.8% in the ipilimumab gro

268 Molecular recurrence-free survival was 43% (95% CI, 33% to 52%) at

269 io 0.75; 95% CI 0.64-0.90; p=0.0013); 3-year recurrence-free survival was 46.5% (95% CI 41.5-51.3) in

270 In the primary outcome analysis, mean recurrence-free survival was 467 days (95% CI, 445-489 d

271 was 65 months (95% CI, 43 to 67 months) and recurrence-free survival was 5.6 months (95% CI, 3 to 11

272 Recurrence-free survival was 64.5% in group A and 70.2%

273 Five-year local recurrence-free survival was 69%.

274 The cumulative VT recurrence-free survival was 75%, 50%, and 25% after 1.5

275 Median follow-up for recurrence-free survival was 8.5 months (IQR 2.9-19.5) i

276 Three-year estimated local recurrence-free survival was 89.2% (95% CI, 0.748 to 0.9

277 The 3-year estimated distant recurrence-free survival was 90.3% (95% CI, 0.797 to 0.9

278 Three-year local recurrence-free survival was 96.9%, metastasis-free surv

279 The 3-year recurrence-free survival was 97.4% (95% CI, 96.4-98.5) i

280 Recurrence-free survival was described using Kaplan-Meie

281 The improved recurrence-free survival was found only in males.

282 Recurrence-free survival was higher in group 1, as compa

283 Recurrence-free survival was higher in the surgery + che

284 Association with overall survival and recurrence-free survival was investigated using the Kapl

285 Recurrence-free survival was modestly less favorable for

286 The final analysis of recurrence-free survival was planned to take place after

287 No difference in recurrence-free survival was seen between patients given

288 Five-year recurrence-free survival was significantly better in gro

289 Five-year recurrence-free survival was significantly poorer in 45F

290 Recurrence-free survival was significantly prolonged in

291 With a median follow-up of 5.8 years, recurrence-free survival was similar for patients treate

292 Recurrence-free survival was the primary end point.

293 ificant independent predictor of overall and recurrence-free survival was time since antecedent pregn

294 Final analysis of recurrence-free survival was triggered in November, 2005

295 e 24-month Kaplan-Meier estimate for orbital recurrence-free survival was worse for the enucleation g

296 The primary endpoint, recurrence-free survival, was significantly longer in th

297 (OS), disease-free survival (DFS), and local recurrence-free survival were compared for patients with

298 than 5 cm, in-hospital morbidity and 5-year recurrence-free survival were similar between the groups

299 months, 3-year disease-free and locoregional recurrence-free survivals were 88% and 96%, respectively

300 easing T-category to significantly impact on recurrence free survival while increasing N-and T-catego